Cargando…

Estimation of the timing of BAP1 mutation in uveal melanoma progression

Uveal melanoma is the most common primary intraocular malignancy. A vast majority of metastasizing tumors have mutations in the BAP1 gene. Here, we investigate the spatiotemporal timing of these mutations. The size of 177 uveal melanomas and 8.3 million individual tumor cells was measured. BAP1 sequ...

Descripción completa

Detalles Bibliográficos
Autores principales: Uner, Ogul E., See, Thonnie Rose O., Szalai, Eszter, Grossniklaus, Hans E., Stålhammar, Gustav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076235/
https://www.ncbi.nlm.nih.gov/pubmed/33903674
http://dx.doi.org/10.1038/s41598-021-88390-6
_version_ 1783684654541307904
author Uner, Ogul E.
See, Thonnie Rose O.
Szalai, Eszter
Grossniklaus, Hans E.
Stålhammar, Gustav
author_facet Uner, Ogul E.
See, Thonnie Rose O.
Szalai, Eszter
Grossniklaus, Hans E.
Stålhammar, Gustav
author_sort Uner, Ogul E.
collection PubMed
description Uveal melanoma is the most common primary intraocular malignancy. A vast majority of metastasizing tumors have mutations in the BAP1 gene. Here, we investigate the spatiotemporal timing of these mutations. The size of 177 uveal melanomas and 8.3 million individual tumor cells was measured. BAP1 sequencing results and BAP1 IHC were available and for 76 (43%) and 101 (57%) of these, respectively. Tumors with a BAP1 mutation had significantly larger volume (2109 vs. 1552 mm(3), p = 0.025). Similarly, tumor cells with loss of BAP1 protein expression had significantly larger volume (2657 vs. 1593 μm(3), p = 0.027). Using observations of the time elapsed between mitoses, the BAP1 mutation was calculated to occur when the primary tumor had a size of a few malignant cells to 6 mm(3), 0.5 to 4.6 years after tumor initiation and at least 9 years before diagnosis. We conclude that BAP1 mutations occur early in the growth of uveal melanoma, well before the average tumor is diagnosed. Its timing coincides with the seeding of micrometastases.
format Online
Article
Text
id pubmed-8076235
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-80762352021-04-27 Estimation of the timing of BAP1 mutation in uveal melanoma progression Uner, Ogul E. See, Thonnie Rose O. Szalai, Eszter Grossniklaus, Hans E. Stålhammar, Gustav Sci Rep Article Uveal melanoma is the most common primary intraocular malignancy. A vast majority of metastasizing tumors have mutations in the BAP1 gene. Here, we investigate the spatiotemporal timing of these mutations. The size of 177 uveal melanomas and 8.3 million individual tumor cells was measured. BAP1 sequencing results and BAP1 IHC were available and for 76 (43%) and 101 (57%) of these, respectively. Tumors with a BAP1 mutation had significantly larger volume (2109 vs. 1552 mm(3), p = 0.025). Similarly, tumor cells with loss of BAP1 protein expression had significantly larger volume (2657 vs. 1593 μm(3), p = 0.027). Using observations of the time elapsed between mitoses, the BAP1 mutation was calculated to occur when the primary tumor had a size of a few malignant cells to 6 mm(3), 0.5 to 4.6 years after tumor initiation and at least 9 years before diagnosis. We conclude that BAP1 mutations occur early in the growth of uveal melanoma, well before the average tumor is diagnosed. Its timing coincides with the seeding of micrometastases. Nature Publishing Group UK 2021-04-26 /pmc/articles/PMC8076235/ /pubmed/33903674 http://dx.doi.org/10.1038/s41598-021-88390-6 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Uner, Ogul E.
See, Thonnie Rose O.
Szalai, Eszter
Grossniklaus, Hans E.
Stålhammar, Gustav
Estimation of the timing of BAP1 mutation in uveal melanoma progression
title Estimation of the timing of BAP1 mutation in uveal melanoma progression
title_full Estimation of the timing of BAP1 mutation in uveal melanoma progression
title_fullStr Estimation of the timing of BAP1 mutation in uveal melanoma progression
title_full_unstemmed Estimation of the timing of BAP1 mutation in uveal melanoma progression
title_short Estimation of the timing of BAP1 mutation in uveal melanoma progression
title_sort estimation of the timing of bap1 mutation in uveal melanoma progression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076235/
https://www.ncbi.nlm.nih.gov/pubmed/33903674
http://dx.doi.org/10.1038/s41598-021-88390-6
work_keys_str_mv AT unerogule estimationofthetimingofbap1mutationinuvealmelanomaprogression
AT seethonnieroseo estimationofthetimingofbap1mutationinuvealmelanomaprogression
AT szalaieszter estimationofthetimingofbap1mutationinuvealmelanomaprogression
AT grossniklaushanse estimationofthetimingofbap1mutationinuvealmelanomaprogression
AT stalhammargustav estimationofthetimingofbap1mutationinuvealmelanomaprogression